Granules India Limited

Equities

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:46 2024-04-16 am EDT 5-day change 1st Jan Change
415.4 INR +1.53% Intraday chart for Granules India Limited -2.30% +2.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit MT
Granules India Unit Gets VAI Status for Virginia Facility MT
Granules India Limited Announces Appointment of Directors CI
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director CI
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations CI
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer CI
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing CI
Transcript : Granules India Limited, Q3 2024 Earnings Call, Jan 23, 2024
Paracetamol maker Granules India posts marginal rise in Q3 profit RE
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit MT
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA MT
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets MT
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets CI
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension MT
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand RE
Transcript : Granules India Limited, Q2 2024 Earnings Call, Nov 09, 2023
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Granules India Gets US FDA's Approval for Generic Drug for GERD Symptoms MT
Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules CI
Indian paracetamol maker Valiant Laboratories lists at 16% premium RE
Granules India Gets US FDA Nod for Hypertension Treatment Drug MT
Granules India Limited Announces the US Food & Drug Administration Approval of its Abbreviated New Drug Application for Losartan Potassium and Hydrochlorothiazide Tablets USP CI
Granules India's Telangana Facility Gets Accreditation from Japanese Regulator MT
Granules India Limited Receives Approval from Brazilian Health Regulatory Agency CI
Chart Granules India Limited
More charts
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Company’s wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
409.2 INR
Average target price
483.4 INR
Spread / Average Target
+18.14%
Consensus
  1. Stock Market
  2. Equities
  3. GRANULES Stock
  4. News Granules India Limited
  5. Granules India : Gets Two Observations from US FDA for Virginia Facility